Business Context and Reporting Period
Company: Mobix Labs, Inc. (MOBX)
Filing Type: Form 8-K (Current Report)
Date of Report: April 4, 2025
Event: Entry into a Material Definitive Agreement for a Registered Direct Offering and concurrent private placement.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic financial performance. Key transaction metrics include:
- Gross Proceeds: Approximately $4 million (before fees and expenses).
- Securities Issued:
- 3,850,000 shares of Class A Common Stock at $0.8202 per share.
- Pre-Funded Warrants to purchase 1,026,860 shares at $0.8201 per warrant.
- Common Warrants to purchase up to 4,876,860 shares at an exercise price of $0.8202.
- Placement Agent Fees: 7.0% cash fee of gross proceeds plus warrants to purchase 682,760 shares (7.0% of total securities sold).
- Expense Reimbursement: Up to $75,000 to the Placement Agent.
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing does not provide current revenue, profit, cash flow, or debt levels. It focuses solely on the terms of the offering.
Material Changes and Warrant Amendments
As part of the transaction, the Company agreed to amend existing Series A and Series B Warrants issued on July 24, 2024:
- Exercise Price Reduction: Reduced from $1.39 to $0.8202 per share for an aggregate of 5,755,396 shares.
- Term Extension: Series B Warrants extended to the greater of 15 months from the initial expiration date or three months from stockholder approval.
- Exercisability: Amended warrants become immediately exercisable upon stockholder approval.
Guidance, Outlook, and Restrictions
Outlook and Closing: The Offerings are expected to close on or about April 7, 2025, subject to customary conditions.
Lock-Up and Issuance Restrictions:
- The Company is restricted from issuing new equity or convertible securities for 60 days after the stockholder approval date.
- The Company is restricted from entering into variable rate transactions until August 29, 2025.
Risks and Contingencies:
- Stockholder Approval: Exercise of Common Warrants and amended Existing Warrants is contingent upon stockholder approval.
- Beneficial Ownership Limits: Purchasers cannot exercise warrants if it would cause them to beneficially own more than 4.99% (or 9.99% at election) of outstanding shares.
- Registration Obligation: The Company must file a registration statement for the resale of Common Warrant Shares within 45 days and have it declared effective within 181 days of closing.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting the 7% placement fee and expenses.
- Confirm the timeline for stockholder approval required to exercise the Common Warrants and amended Existing Warrants.
- Review the full text of the Purchase Agreement (Exhibit 10.2) for specific exceptions to the lock-up provisions.
- Monitor the filing of the registration statement for the resale of Common Warrant Shares to ensure compliance with the 45-day deadline.
- Assess the dilution impact of the 4,876,860 Common Warrants and 5,755,396 amended Existing Warrants on existing shareholders.